Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently A number of malignancies such as melanoma, ovarian cancer, renal cell carcinoma and glioma produce an immunosuppressive microenvironment. 1 We have shown that acute myeloid leukemia (AML) tumor-derived supernatant (TSN) is immunosuppressive, preventing T-cell activation, proliferation and apoptosis.
2 AML TSN prevents T-cell activation by profoundly inhibiting the production of the Th1 cytokines IFN-g and IL-2 and inhibits cell cycle entry before the G 0 -G 1 commitment point, 3 by preventing the phosphorylation of retinoblastoma protein (pRb) and the induction of c-Myc. 1 In addition, AML TSN delays the apoptosis of both normal hematopoietic and leukemic blast cells; 2 however, it was unknown as to whether this is a unique feature of AML or extended to other myeloid malignancies. We now show that T-cell apoptosis is inhibited by TSN from the cells of 11/12 cases of chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS) tested, irrespective of disease severity. We suggest that myeloid malignancies generate an antiapoptotic microenvironment, which favors the survival of malignant cells. Apoptosis of normal T cells is inhibited and the AML TSN renders these T cells functionally incompetent. In contrast, IL-2 production and phosphorylation of the pRb is inhibited by the majority of high-grade and some low-grade disease cases, whereas c-Myc induction is inhibited only by AML TSN. This strongly suggests the presence of multiple factors in TSN that target apoptotic and cell cycle processes individually.
Accelerated apoptosis of hematopoietic cells in MDS may account for the typical marrow hypercellularity but peripheral blood cytopenias. 4 Leukemic transformation in MDS may be associated with inhibition of apoptotic mechanisms and an increased degree of neoplastic cell survival. C-Myc can independently sensitize cells to apoptosis as well as playing an essential role in cell proliferation 5 and c-Myc amplification has been described in cases of transformation from MDS to AML. The Bcr-Abl fusion gene has the capacity to suppress apoptosis in vitro and the mechanisms favoring the growth advantage of Philadelphia-positive cells in CML may be in part secondary to enhanced survival of CML malignant clones. 6 C-Myc expression is also required for the oncogenic effects of Bcr-Abl and may play an important role in CML progression.
The effects of IL-2 production in MDS patients has been studied and found to be dysregulated, with both IL-2R and IL-2 production being impaired in normal T cells. 7 Low levels of IL-2 have been reported in T cells selected from CML patients and peripheral blood mononuclear cells from CML patients have demonstrated markedly defective IL-2 production. 8 pRb is a negative regulator of cell proliferation, induces differentiation and is also an inhibitor of apoptosis. It has been reported that malignant cells of both solid tumors and leukemias produce factors that inhibit cells of the immune system, which may help them evade immune surveillance. 1 In the present study, we examined whether the previously noted specific effects on T-cell cytokine production, cell cycle inhibition, pRb phosphorylation, c-Myc induction and apoptosis are exclusive to AML cells, or occur in other lower grade myeloid malignancies, namely MDS and chronic phase (CP) CML.
Primary PBMNCs were obtained from normal donors by density gradient separation 1 and T cells were negatively selected. 1 Tumor cells were obtained from peripheral blood/ leucapheresis bone marrow samples. Patients included CP CML (n ¼ 6), low-risk MDS (n ¼ 6), myeloid blast crisis CML (n ¼ 1) and secondary AML (sAML n ¼ 1), AML (n ¼ 4), ( Table 1) . The purified T cells were cultured either alone, or in the presence of primary tumor cells, which were contained in a cell culture insert, thereby preventing cell:cell contact. For intracellular IL-2 detection, PBMNCs were activated, fixed and permeabilized (Fix and Perm; Caltag Laboratories, Burlingame, CA, USA) then labeled with a FITC conjugated anti-IL-2 (Serotec, Oxford, UK). 1 Flow cytometric analysis was performed using a FACSCalibur (BD Biosciences, Oxford, UK). For Western blotting analysis, T cells were activated and then lysates prepared.
1 Membranes were incubated with Abs to c-Myc (clone 9E10 mAb), (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-pRb (S807/811) and pRb (New England Biolabs, Little Chalfont, Hertfordshire, UK). T-cell apoptosis was analyzed by flow cytometry by incubating T cells with tumor cells as before. T cells were then harvested at designated time intervals and Tcell apoptosis was assessed by Annexin V-FITC and propidium iodide (PI) staining (Sigma-Aldrich, Poole, Dorset, UK).
We first determined whether cells from patients with indolent (CP CML and MDS refractory anemia (RA), 5q-syndrome, chronic myelomonocytic leukemia (CMML)) and aggressive (accelerated phase (AP) CML, sAML) myeloid diseases inhibited T-cell activation, judged by IL-2 production, cell cycle entry, induction of c-Myc and pRb phosphorylation by cyclin D-cdk4/6. These data were compared with four new AML cases. IL-2 production was inhibited by TSN from 4/6 cases of more advanced stage myeloid disease (AML n ¼ 5, AP-CML n ¼ 1), but only in 4/12 cases of less aggressive malignancies (MDS (RA) n ¼ 5, CMML n ¼ 1, CP-CML n ¼ 6) (Figure 1a) . Inhibition of pRb phosphorylation occurred in 5/5 evaluable cases of advanced stage myeloid disease (AML n ¼ 4, AP-CML n ¼ 1) and in 7/12 evaluable lower grade myeloid malignancies (Figure 1b) . The most striking difference between the indolent and aggressive diseases was in their inhibition of c-Myc. The induction of c-Myc was inhibited in 4/6 evaluable cases of advanced stage disease (AML n ¼ 5, AP-CML n ¼ 1), but was normal in all other cases (inhibition 0/12) (Figure 1c) . In contrast, marked inhibition of T-cell apoptosis was observed in 14/15 of evaluable cases, 4/4 with advanced myeloid disease and 10/11 of the less advanced malignancies (Figure 1d) .
It would appear that the effect of AML TSN on T-cell activation and cell cycle entry is more marked in disorders 
Correspondence associated with an excess of blast cells. Our previous studies had shown T-cell IL-2 production to be inhibited by TSN from 18/20 cases of AML but here, inhibition only occurred with TSN from 4/12 cases of less aggressive malignancies. The induction of c-Myc was restricted to advanced disease but inhibition of pRb phosphorylation was noted in all cases of advanced disease and in 6/11 lower grade malignancies. In contrast, marked inhibition of T-cell apoptosis was observed in the majority of cases, irrespective of disease severity. Myeloid malignancies thus secrete factors that might produce an antiapoptotic microenvironment in vivo. This is independent of their ability to inhibit induction of IL-2 and c-Myc as well as the phosphorylation of pRb. These data suggest that inhibition of cell cycle entry (G 0 -G 1 ) and IL-2 production are distinct processes that are both inhibited in more aggressive myeloid malignancies. When T cells are deprived of IL-2, proapoptotic proteins can be up regulated and it is known that IL-2 production can overcome programmed cell death. However, in our studies with TSN from myeloid malignancies, there was no correlation between IL-2 inhibition and T-cell survival.
These results show that all stages of myeloid disease studied are associated with secretion of antiapoptotic factors but that the immunosuppressive effect of myeloid malignancies depends upon disease stage, with more marked effects in the advanced/ aggressive phase. This may contribute to the well-recognized difference in sensitivity to adoptive immunotherapy between acute and chronic myeloid leukemias. The elaboration of antiapoptotic factors(s) may contribute to the survival of tumor Figure 1 T-cell IL-2 production, pRb phosphorylation, c-Myc induction and apoptosis in the presence of TSN from patients with myeloid malignancies. (a) IL-2 production. Quiescent T cells were cultured without stimulus and also stimulated with PMA/ionomycin either alone or in the presence of cells from patients with myeloid malignancies. IL-2 production was assayed after 24 h by flow cytometry. It was inhibited by 4/4 cases of AML, 3/6 cases of CP-CML but only 1/6 cases of low grade MDS and examples of which are shown. (b) pRb phosphorylation. T cells were cultured as described in (a) and phosphorylation of pRb at the cdk4/6-cyclin D-specific sites S 807/811 was determined by Western blotting. pRb phosphorylation occurs 24 h poststimulation but this was inhibited in all evaluable cases of AML, 3/6 cases of CP-CML and 3/5 cases of low grade MDS and examples of each response is shown. (c) C-Myc induction. T cells were cultured as described in (a) and c-Myc expression was determined after 5 h by Western blotting. Analysis of c-Myc expression was determined on the same blot as that for pRb phosphorylation, therby pRb protein analysis acted as a loading control for both. Induction of c-Myc was inhibited by 4/4 cases of primary AML but not by other diseases tested. (d) Apoptosis. T cells were cultured for 13 days as described in (a) without stimulation and the proportion of apoptotic cells was measured by Annexin V and PI staining. Only 3% of T cells were viable when cultured alone, but their viability was greatly enhanced by the presence of malignant cells from almost all patients tested, regardless of disease severity. cells both directly through paracrine and autocrine effects and indirectly by promoting the survival of a pool of functionally incompetent T cells in the leukemic microenvironment. The differential effect on T-cell activation/proliferation and apoptosis strongly suggests that TSN contains multiple factors, which target these processes individually. Our results highlight the complexity of immune dysfunction within the leukemic microenvironment. Characterization of these findings will be important for understanding the mechanisms of disease progression and in the design of immunologically based strategies. 
